Progress in PDE4 targeted therapy for inflammatory diseases.
- Author:
Shun-de SONG
1
;
Hui-fang TANG
1
Author Information
1. Zhejiang Respiratory Drugs Research Laboratory， Zhejiang University School of Medicine， Hangzhou 310058， China.
- Publication Type:Journal Article
- MeSH:
Aminopyridines;
pharmacology;
Aminoquinolines;
pharmacology;
Arthritis;
drug therapy;
Asthma;
drug therapy;
Benzamides;
pharmacology;
Cyclopropanes;
pharmacology;
Dermatitis;
drug therapy;
Humans;
Inflammation;
drug therapy;
Inflammatory Bowel Diseases;
drug therapy;
Phosphodiesterase 4 Inhibitors;
pharmacology;
Pulmonary Disease, Chronic Obstructive;
drug therapy;
Sulfones;
pharmacology;
Thalidomide;
analogs & derivatives;
pharmacology;
Thiazoles;
pharmacology
- From:
Journal of Zhejiang University. Medical sciences
2014;43(3):353-358
- CountryChina
- Language:Chinese
-
Abstract:
cAMP-specific phosphodiesterase type 4 (PDE4) is one of the hot targets for treatment of inflammatory diseases. PDE4 inhibitors can suppress inflammation by increasing the concentration of cAMP in inflammatory cells. The efficacy and safety evaluations of several PDE4 inhibitors are currently carried on in clinical trials, for example GSK256066 in asthma, roflumilast and GSK256066 in chronic obstructive pulmonary disease, tetomilast in inflammatory bowel disease, and apremilast in dermatitis and arthritis etc. This article reviews the recent progress on PDE4-targeted therapy for inflammatory diseases.
